Phase III DeLLphi-305 data show tarlatamab plus durvalumab extended median overall survival to 21.1 months versus 12.7 months with durvalumab alone in extensive-stage small cell lung cancer maintenance.

ONCOLOGY · CLINICAL TRIAL · NOVEMBER 1, 2026 · UNITED STATES
The Phase III DeLLphi-305 trial, sponsored by Amgen with partial funding from AstraZeneca, reported a hazard ratio (HR) of 0.42 (95% confidence interval [CI], 0.32–0.54; P < .001) for overall survival (OS) in patients with extensive-stage small cell lung cancer (ES-SCLC) receiving first-line maintenance therapy with tarlatamab-dlle (Imdelltra) plus durvalumab (Imfinzi) versus durvalumab alone, according to the prespecified interim analysis presented at the 2026 European Society for Medical Oncology (ESMO) Congress and simultaneously published in The New England Journal of Medicine (NEJM).
The absolute numbers reinforce the relative figure. At a prespecified interim analysis triggered at 243 deaths — a 61% information fraction — median OS was 21.1 months (95% CI, 20.8–not estimable) in the combination arm versus 12.7 months (95% CI, 11.2–14.8) with durvalumab alone, per OncLive’s reporting of the trial data. The 12-month OS rates were 79% versus 53%, respectively. Jacob Sands, MD, of Dana-Farber Cancer Institute in Boston, who presented the data during the Presidential Symposium, stated: ‘DeLLphi-305 outcomes support tarlatamab plus durvalumab as a new standard of care first-line maintenance therapy in ES-SCLC.’
HR 0.42
The hazard ratio for death with tarlatamab plus durvalumab versus durvalumab alone was 0.42 (95% CI, 0.32–0.54; P < .001) at the DeLLphi-305 interim analysis, per OncLive’s reporting of the NEJM publication.
Amgen had announced in September 2026 that the trial met its primary OS endpoint at the planned interim analysis. The ESMO presentation provided the granular data behind that announcement.
A survival signal that extends across high-risk subgroups
The trial enrolled 563 adults with ES-SCLC and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 whose disease had not progressed after four cycles of induction platinum/etoposide plus durvalumab. Patients were randomized 1:1 to tarlatamab at 10 mg every two weeks plus durvalumab at 1,500 mg every four weeks, or durvalumab alone at 1,500 mg every four weeks. Randomization was stratified by brain and/or liver metastases, response to induction chemoimmunotherapy, and prior platinum type.
Among patients with current or prior brain metastases (n = 111), the hazard ratio was 0.49 (95% CI, 0.26–0.93). Among those with current or prior liver metastases (n = 183), it was 0.41 (95% CI, 0.28–0.61). Patients with stable disease after induction showed a hazard ratio of 0.40 (95% CI, 0.19–0.85; n = 64), per the trial data reported by OncLive.
Progression-free survival (PFS), the key secondary endpoint, followed the same direction. At a median follow-up of 13.9 months in both arms, median PFS was 7.4 months (95% CI, 5.6–9.1) with the combination versus 1.9 months (95% CI, 1.9–2.0) with durvalumab alone (hazard ratio, 0.34; 95% CI, 0.28–0.42; P < .001). The 12-month PFS rates were 38% versus 10%.
Among patients with measurable disease at randomization, the objective response rate (ORR) was 26.4% (95% CI, 20.9%–32.5%) with the combination versus 4.1% (95% CI, 2.0%–7.4%) with durvalumab alone (P < .001). The median duration of response was 12.7 months (95% CI, 7.4–not estimable) versus 5.6 months (95% CI, 3.6–not estimable); the 12-month duration of response rate in the tarlatamab/durvalumab arm was 52%. Sands noted that response rate carries limited interpretive weight in the maintenance setting, where patients enter after already benefiting from induction therapy.
The Americas subgroup and the payer calculus
One number will draw disproportionate scrutiny from US formulary committees. In patients enrolled in the Americas (n = 75), the hazard ratio for OS was 0.82 (95% CI, 0.39–1.71) — a wide interval consistent with a small subgroup and statistically inconclusive. The overall trial result is driven by the global population, and subgroup analyses of this size are hypothesis-generating rather than definitive. Still, payers and oncology medical directors operating within US coverage frameworks will weigh this regional signal alongside the headline result when evaluating formulary placement and prior-authorization criteria.
The safety profile adds a layer of complexity to the coverage decision. Grade 3 or higher treatment-emergent adverse events occurred in 46.8% of patients in the combination arm versus 40.6% in the durvalumab-alone arm. Treatment-related adverse events (TRAEs) of any grade were reported in 95.0% versus 52.2%, and grade 3 or higher TRAEs in 20.9% versus 10.8%. TRAEs led to tarlatamab discontinuation in 3.2% of patients. No fatal TRAEs occurred in the combination arm; two fatal TRAEs (0.7%) occurred in the durvalumab-alone arm. The median duration of treatment was 46.9 weeks (interquartile range, 16.4–65.6) with the combination versus 8.1 weeks (interquartile range, 4.1–20.1) with durvalumab alone — a gap that reflects both the survival benefit and the longer exposure to adverse-event risk.
Cytokine release syndrome (CRS), a known class effect of bispecific T-cell engager (BiTE) molecules, occurred in 49.6% of patients in the combination arm versus 1.4% with durvalumab alone; grade 3 CRS occurred in one patient (0.4%), with no grade 4 or fatal events. The trial required on-site monitoring for one to two hours after the first two tarlatamab doses, or six to eight hours in certain regions. In September 2026, the FDA shortened the labeled monitoring period after the first two doses of tarlatamab to six to eight hours, from the previously recommended 22 to 24 hours, according to Amgen — a label update that may ease the logistical burden on infusion centers but does not eliminate the monitoring requirement.
Current first-line maintenance options in ES-SCLC include Roche’s atezolizumab (Tecentriq) and AstraZeneca’s durvalumab (Imfinzi) — which is, notably, the backbone of the DeLLphi-305 control arm and the combination partner in the experimental arm. Jazz Pharmaceuticals’ lurbinectedin (Zepzelca) in combination with Tecentriq received FDA approval in October 2025 as maintenance treatment for adults with ES-SCLC whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin, and etoposide, according to Jazz. The DeLLphi-305 result does not include a head-to-head comparison with any of these regimens.
Tarlatamab already holds full FDA approval for adults with ES-SCLC whose disease progressed after platinum-based chemotherapy. The FDA granted accelerated approval in May 2024, based on a trial in which the drug shrank tumors in 40% of patients, per BioPharma Dive, and converted it to full approval in November 2025 on the basis of the Phase III DeLLphi-304 trial, according to Amgen. A label expansion into first-line maintenance would require a supplemental biologics license application and FDA review; Amgen said in September 2026 that it plans to share the DeLLphi-305 data with regulatory authorities, and OS follow-up is ongoing, per OncLive.
What to Watch
- Whether and when Amgen files a supplemental biologics license application with the FDA for a first-line maintenance indication — the filing timeline and the agency’s review clock will determine when the label can formally support the DeLLphi-305 regimen in US clinical practice.
- Mature OS data from DeLLphi-305, with follow-up ongoing as of the July 7, 2026 data cutoff; the interim analysis captured 61% of planned events, leaving the survival curves subject to further movement.
- US payer coverage decisions and prior-authorization criteria for the combination regimen, particularly how formulary committees weight the Americas subgroup hazard ratio of 0.82 against the global result of 0.42.
The deeper tension in DeLLphi-305 is structural: AstraZeneca’s durvalumab is simultaneously the standard-of-care comparator that the combination beat and the partner drug without which the combination cannot be administered. Any formulary or guideline that endorses tarlatamab plus durvalumab as first-line maintenance locks in durvalumab as a required co-administration — a dependency that complicates competitive displacement in a way that a clean head-to-head between two independent regimens would not.
DeLLphi-305 · Tarlatamab + Durvalumab vs Durvalumab Alone
| Tarlatamab + Durvalumab (n=282) | Durvalumab Alone (n=281) | |
|---|---|---|
| Median overall survival | 21.1 months (95% CI, 20.8–not estimable) | 12.7 months (95% CI, 11.2–14.8) |
| 12-month overall survival rate | 79% | 53% |
| Median progression-free survival | 7.4 months (95% CI, 5.6–9.1) | 1.9 months (95% CI, 1.9–2.0) |
| 12-month progression-free survival rate | 38% | 10% |
| Objective response rate (measurable disease) | 26.4% (95% CI, 20.9%–32.5%) | 4.1% (95% CI, 2.0%–7.4%) |
| Grade 3+ treatment-related adverse events | 20.9% | 10.8% |
Why this is relevant
Patients
Adults with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after induction chemoimmunotherapy may gain a maintenance option associated with a median overall survival of 21.1 months versus 12.7 months on durvalumab alone, though grade 3 or higher treatment-related adverse events occurred in 20.9% of patients on the combination, requiring ongoing clinical monitoring.
Industry
Amgen’s DeLLphi-305 result, if it supports a supplemental biologics license application, would expand tarlatamab’s addressable population from second-line into first-line maintenance; the regimen structurally requires AstraZeneca’s durvalumab as a co-administration, creating a commercial dependency that complicates competitive displacement for both companies.
Payers
US formulary committees will weigh the global hazard ratio of 0.42 against the Americas subgroup result of 0.82 (95% CI, 0.39–1.71; n = 75 patients), a wide and statistically inconclusive interval that may inform prior-authorization criteria and coverage tier placement ahead of any formal label expansion.
Regulators
The FDA updated the tarlatamab label in September 2026 to shorten the required post-dose monitoring window after the first two doses to six to eight hours, a change that may ease infusion-center logistics but does not eliminate the monitoring requirement.
Sources: OncLive: DeLLphi-305 Data Support Frontline Maintenance Tarlatamab Plus Durvalumab as a New SOC in ES-SCLC · Amgen: IMDELLTRA in combination with IMFINZI reduced risk of death by 58% in first-line ES-SCLC (October 24, 2026) · Amgen: IMDELLTRA in combination with IMFINZI demonstrated landmark improvement in overall survival (September 8, 2026) · Amgen: FDA approves reduced monitoring time for first two doses of IMDELLTRA (September 14, 2026) · Amgen: FDA grants full approval to IMDELLTRA in ES-SCLC (November 19, 2025) · Jazz Pharmaceuticals: FDA approves Zepzelca and atezolizumab as first-line maintenance therapy (October 2, 2025) · BioPharma Dive: FDA approves Amgen drug for tough-to-treat form of lung cancer
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.







